KR102342776B1 - (S)-2-((2-((S)-4-(다이플루오로메틸)-2-옥소옥사졸리딘-3-일)-5,6-다이하이드로벤조[f]이미다조[1,2-d][1,4]옥사제핀-9-일)아미노)프로판아미드의 다형체 및 고체 형태, 및 이의 제조 방법 - Google Patents

(S)-2-((2-((S)-4-(다이플루오로메틸)-2-옥소옥사졸리딘-3-일)-5,6-다이하이드로벤조[f]이미다조[1,2-d][1,4]옥사제핀-9-일)아미노)프로판아미드의 다형체 및 고체 형태, 및 이의 제조 방법 Download PDF

Info

Publication number
KR102342776B1
KR102342776B1 KR1020197031575A KR20197031575A KR102342776B1 KR 102342776 B1 KR102342776 B1 KR 102342776B1 KR 1020197031575 A KR1020197031575 A KR 1020197031575A KR 20197031575 A KR20197031575 A KR 20197031575A KR 102342776 B1 KR102342776 B1 KR 102342776B1
Authority
KR
South Korea
Prior art keywords
cancer
crystalline
polymorph
gdc
crystalline anhydride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197031575A
Other languages
English (en)
Korean (ko)
Other versions
KR20190133724A (ko
Inventor
파로마 차크라바르티
총 한
션 엠 켈리
카티크 나가푸디
스콧 새비지
Original Assignee
에프. 호프만-라 로슈 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프. 호프만-라 로슈 아게 filed Critical 에프. 호프만-라 로슈 아게
Publication of KR20190133724A publication Critical patent/KR20190133724A/ko
Application granted granted Critical
Publication of KR102342776B1 publication Critical patent/KR102342776B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
KR1020197031575A 2017-04-28 2018-04-26 (S)-2-((2-((S)-4-(다이플루오로메틸)-2-옥소옥사졸리딘-3-일)-5,6-다이하이드로벤조[f]이미다조[1,2-d][1,4]옥사제핀-9-일)아미노)프로판아미드의 다형체 및 고체 형태, 및 이의 제조 방법 Active KR102342776B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762491812P 2017-04-28 2017-04-28
US62/491,812 2017-04-28
PCT/EP2018/060820 WO2018197653A1 (en) 2017-04-28 2018-04-26 Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production

Publications (2)

Publication Number Publication Date
KR20190133724A KR20190133724A (ko) 2019-12-03
KR102342776B1 true KR102342776B1 (ko) 2021-12-23

Family

ID=62492573

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197031575A Active KR102342776B1 (ko) 2017-04-28 2018-04-26 (S)-2-((2-((S)-4-(다이플루오로메틸)-2-옥소옥사졸리딘-3-일)-5,6-다이하이드로벤조[f]이미다조[1,2-d][1,4]옥사제핀-9-일)아미노)프로판아미드의 다형체 및 고체 형태, 및 이의 제조 방법

Country Status (13)

Country Link
US (4) US20180339997A1 (enExample)
EP (2) EP3615541B1 (enExample)
JP (2) JP6998969B2 (enExample)
KR (1) KR102342776B1 (enExample)
CN (1) CN110650963B (enExample)
AU (1) AU2018259089B2 (enExample)
CA (1) CA3048591A1 (enExample)
ES (1) ES3027566T3 (enExample)
IL (3) IL298518B2 (enExample)
MX (1) MX394540B (enExample)
PL (1) PL3615541T3 (enExample)
TW (1) TWI826373B (enExample)
WO (1) WO2018197653A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20211775A1 (es) 2015-07-02 2021-09-08 Hoffmann La Roche Compuestos de benzoxacepina oxazolidinona y metodos de uso
ES2953833T3 (es) 2016-12-15 2023-11-16 Hoffmann La Roche La invención se refiere a procedimientos de preparación de compuestos de benzoxacepina oxazolidinona e intermedios útiles
MX394540B (es) 2017-04-28 2025-03-21 Hoffmann La Roche Polimorfos y formas solidas de la (s)-2-((2-((s)-4-(difluorometil)-2-oxooxazolidin-3-il)-5,6-dihidrobenzo[f]imidazo[1,2-d] [1,4]oxazepin-9-il)amino)propanamida, y metodos de produccion.
CN112313202A (zh) * 2019-05-21 2021-02-02 江苏众强药业有限公司 曲前列尼尔钠盐新晶型及制备方法
MX2022000279A (es) * 2019-07-07 2022-02-03 Olema Pharmaceuticals Inc Regimenes de antagonistas del receptor de estrogeno.
EP4021450B1 (en) 2019-08-26 2025-11-05 Arvinas Operations, Inc. Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
KR20220119610A (ko) * 2019-11-25 2022-08-30 상하이 한서 바이오메디컬 컴퍼니 리미티드 3개의 융합된 고리 유도체-함유 염 또는 결정 형태 및 이의 약학 조성물
CN112830935B (zh) * 2019-11-25 2023-12-22 上海翰森生物医药科技有限公司 含三并环类衍生物自由碱的晶型及其药物组合物
TWI801730B (zh) * 2020-04-07 2023-05-11 神雲科技股份有限公司 具系統設定資料同步功能的伺服器
TW202440096A (zh) 2023-03-24 2024-10-16 美商亞文納營運公司 雌激素受體降解劑之給藥方案

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170015678A1 (en) * 2015-07-02 2017-01-19 Genentech, Inc. Benzoxazepin oxazolidinone compounds and methods of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846824A (en) 1994-02-07 1998-12-08 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
US6274327B1 (en) 1992-04-13 2001-08-14 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
GB9208135D0 (en) 1992-04-13 1992-05-27 Ludwig Inst Cancer Res Polypeptides having kinase activity,their preparation and use
ES2444779T3 (es) * 2009-09-28 2014-02-26 F. Hoffmann-La Roche Ag Compuestos de benzoxazepina inhibidores de la PI3K y su utilización en el tratamiento de cáncer
US9012464B2 (en) 2010-11-25 2015-04-21 Ratiopharm Gmbh Salts and polymorphic forms of Afatinib
MX356804B (es) 2013-12-16 2018-06-13 Hoffmann La Roche Polimorfos de 2-(4-(2-(1-isopropil-3-metil-1h-1,2,4-triazol-5-il)- 5,6-dihidrobenzo[f]imidazol[1,2-d][1,4]oxazepin-9-il)-1h-pirazol- 1-il)-2-metilpropanamida, metodos de produccion, y usos farmaceuticos de los mismos.
ES2953833T3 (es) * 2016-12-15 2023-11-16 Hoffmann La Roche La invención se refiere a procedimientos de preparación de compuestos de benzoxacepina oxazolidinona e intermedios útiles
MX394540B (es) 2017-04-28 2025-03-21 Hoffmann La Roche Polimorfos y formas solidas de la (s)-2-((2-((s)-4-(difluorometil)-2-oxooxazolidin-3-il)-5,6-dihidrobenzo[f]imidazo[1,2-d] [1,4]oxazepin-9-il)amino)propanamida, y metodos de produccion.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170015678A1 (en) * 2015-07-02 2017-01-19 Genentech, Inc. Benzoxazepin oxazolidinone compounds and methods of use

Also Published As

Publication number Publication date
US12410189B2 (en) 2025-09-09
CN110650963A (zh) 2020-01-03
IL298518B2 (en) 2025-05-01
US20230167128A1 (en) 2023-06-01
JP6998969B2 (ja) 2022-02-10
WO2018197653A1 (en) 2018-11-01
US11028100B2 (en) 2021-06-08
AU2018259089A1 (en) 2019-07-04
AU2018259089A9 (en) 2019-10-10
CA3048591A1 (en) 2018-11-01
IL298518B1 (en) 2025-01-01
EP4534148A3 (en) 2025-05-21
IL267464A (en) 2019-08-29
BR112019013292A2 (pt) 2019-12-10
JP2021181446A (ja) 2021-11-25
WO2018197653A9 (en) 2019-09-19
US11591345B2 (en) 2023-02-28
JP2020517713A (ja) 2020-06-18
PL3615541T3 (pl) 2025-06-23
US20180339997A1 (en) 2018-11-29
ES3027566T3 (en) 2025-06-16
IL267464B2 (en) 2023-05-01
IL267464B1 (en) 2023-01-01
EP3615541B1 (en) 2025-03-19
CN110650963B (zh) 2022-09-27
EP4534148A2 (en) 2025-04-09
KR20190133724A (ko) 2019-12-03
IL298518A (en) 2023-01-01
IL317762A (en) 2025-02-01
EP3615541A1 (en) 2020-03-04
TW201843160A (zh) 2018-12-16
US20210094970A1 (en) 2021-04-01
MX2019012507A (es) 2019-12-19
US20200399286A1 (en) 2020-12-24
MX394540B (es) 2025-03-21
TWI826373B (zh) 2023-12-21
EP3615541C0 (en) 2025-03-19
AU2018259089B2 (en) 2022-05-12

Similar Documents

Publication Publication Date Title
KR102342776B1 (ko) (S)-2-((2-((S)-4-(다이플루오로메틸)-2-옥소옥사졸리딘-3-일)-5,6-다이하이드로벤조[f]이미다조[1,2-d][1,4]옥사제핀-9-일)아미노)프로판아미드의 다형체 및 고체 형태, 및 이의 제조 방법
CA2900322C (en) Solid forms of the selective cdk4/6 inhibitor compound acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8h-pyrido[2,3-d]pyrimidin-7-one
JP2018511634A (ja) Ｂ−ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用
JP2018080179A (ja) ２−（４−（２−（１−イソプロピル−３−メチル−１Ｈ−１，２，４−トリアゾール−５−イル）−５，６−ジヒドロベンゾ［ｆ］イミダゾ［１，２−ｄ］［１，４］オキサゼピン−９−イル）−１Ｈ−ピラゾール−１−イル）−２−メチルプロパンアミドの多形、それらの生成方法及び薬学的使用
HK40124018A (en) Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production
HK40020487A (en) Polymorphs and solid forms of gdc-0077, and methods of production thereof
HK40020487B (en) Polymorphs and solid forms of gdc-0077, and methods of production thereof
BR112019013292B1 (pt) Polimorfos anidratos cristalinos, polimorfo triidrato cristalino, composições farmacêuticas, processo para preparar um polimorfo cristalino e uso de um polimorfo cristalino
HK1223101B (zh) Gdc-0032的多晶型物、其制备方法和药物用途
HK40003818A (en) Polymorphs of gdc-0032, methods of production, and pharmaceutical uses thereof

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20191025

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20191025

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210423

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20211129

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20211220

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20211221

End annual number: 3

Start annual number: 1

PG1601 Publication of registration